The pharmacological management of depression
Open accessThe DOI matches its Crossref record; 125 of the 125 references it cites were found in a registry or an index.
Abstract
Depressive disorders are common, recurrent, and chronic, and require treatment A review of the symptom picture and current drug targets demonstrates the need for accurate assessment of depression severity, including suicidality. The initial focus of treatment is rapid resolution of symptoms during an acute phase, followed by continuation. Maintenance treatment is indicated if the risk of recurrence is high. The range of available medications is considerable and the benefit/risk ratio is acceptable. Depression is diagnosable across the life span and treatable at every age (although recent disagreement has arisen with regard to young patients). Comorbidity, both psychiatric and medical, need to be assessed, as does the possible presence of two subtypes of depression (psychotic and bipolar) often requiring different interventions. It is expected that the next generation of antidepressants would be associated with more specific disease and outcome biomarkers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cognitive Therapy for Depression: (675542012-001)
(2012) · PsycEXTRA Dataset · doi:10.1037/e675542012-001 · Cited by 9,663
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E., & Wang, P. S. (2003) · JAMA · doi:10.1001/jama.289.23.3095 · Cited by 7,988 · cited 1×
“2 million adults) in a recent survey.(1) According to the World Health Organization’s Global Burden of Disease Report,(2) major depression was the fourth leading cause of disease burden worldwide in 1990.”
Background(1996) · Cited by 6,884
(1984) · The Lancet · doi:10.1016/s0140-6736(84)92810-1 · Cited by 2,925
Depression Following Myocardial Infarction: Impact on 6-Month Survival
Frasure-Smith, N. (1993) · JAMA · doi:10.1001/jama.1993.03510150053029 · Cited by 1,939
Sertraline treatment of major depression in patients with acute MI or unstable angina
Glassman, A. H. (2002) · JAMA · doi:10.1001/jama.288.6.701 · Cited by 1,414
Interpersonal Psychotherapy Of Depression
Klerman, G. L. (1984) · Medical Entomology and Zoology · Cited by 1,315
Three-Year Outcomes for Maintenance Therapies in Recurrent Depression
Frank, E. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810240013002 · Cited by 1,297
Self-citationThe cellular neurobiology of depression
Manji, H. K., Drevets, W. C., & Charney, D. S. (2001) · Nature Medicine · doi:10.1038/87865 · Cited by 1,182 · cited 1×
“Most recently, attention has moved from intrasynaptic changes in neurotransmitter levels to changes in intracellular signaling pathways.(9) In an important review, Manji and colleagues(9) raise the possibility that depression may be associated with impairments in signaling pathways that are considered important for th…”
Background
Research works printed but not linked: 6
- Richelson E. The clinical relevance of antidepressant interactions with neurotransmitter transporters and receptors. Psychopharmacol Bull. 2002 36 133 149 12858153
- Beck A. Rush A. Shaw B. Emery G. Cognitive Therapy of Depression. New York, NY: Guilford Press; 1979
- Goldsmith SK. Pellmar TC. Kleinman AM. Bunney WE. eds Institute of Medicine, National Academy of Sciences: Reducing Suicide, a National Imperative. Washington, DC: The National Academies Press; 2002 25057611
- Paykel ES. Epidemiology of refractory depression. In: Nolen WA, Zohar J, Roose SP, Amsterdam JD, eds. Refractory Depression: Current Strategies and Future Directions. New York, NY: Wiley; 1994 3 18
- Keller M. Ryan ND. Strober M. et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry. 2001 40 762 772 11437014 · DOI · Paper page
- Geddes JR. Butler R. Depressive Disorders in Adults: Clinical Evidence. London, UK: BMJ Publishing Group; 2002
Cited by
Baldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365
Sexual Dysfunction, Depression, and the Impact of Antidepressants
Kennedy, S. H., & Rizvi, S. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31819c76e9 · Cited by 338
Johnston, K. M., Powell, L. C., Anderson, I. M., Szabo, S., & Cline, S. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.06.045 · Cited by 321
Lekman, M., Laje, G., Charney, D., Rush, A. J., Wilson, A. F., Sorant, A. J. M., Lipsky, R., Wisniewski, S. R., Manji, H., McMahon, F. J., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.10.026 · Cited by 284
Ricken, R., Ulrich, S., Schlattmann, P., & Adli, M. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.04.003 · Cited by 224
Hennings, J. M., Owashi, T., Binder, E. B., Horstmann, S., Menke, A., Kloiber, S., Dose, T., Wollweber, B., Spieler, D., Messer, T., et al. (2009) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2008.05.002 · Cited by 195
Min, J., Lee, N.-B., Lee, C., Lee, C., & Chae, J. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.12.026 · Cited by 128
“patients fail to achieve remission with persistent residual depressive symptoms (Kupfer, 2005; Rush et al., 2006).”
BackgroundThe Gut Microbiota Links Dietary Polyphenols With Management of Psychiatric Mood Disorders
Westfall, S., & Pasinetti, G. M. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01196 · Cited by 113
Sartorius, N., Baghai, T. C., Baldwin, D. S., Barrett, B., Brand, U., Fleischhacker, W., Goodwin, G., Grunze, H., Knapp, M., Leonard, B. E., et al. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707008255 · Cited by 98
Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse
Iovieno, N., van Nieuwenhuizen, A., Clain, A., Baer, L., & Nierenberg, A. A. (2011) · Depression and Anxiety · doi:10.1002/da.20768 · Cited by 98
“Clinical trials have demonstrated that 30–40% of depressed patients fail to respond to first-line antidepressant treatment despite adequate adherence, dose, and duration, and about two-thirds fail to achieve remission after multiple treatment trials;[1] Recent analyses of the STAR D study,[2] in fact, showed high rate…”
BackgroundTargeting inflammation: a potential approach for the treatment of depression
Bhatt, S., Devadoss, T., Jha, N. K., Baidya, M., Gupta, G., Chellappan, D. K., Singh, S. K., & Dua, K. (2022) · Metabolic Brain Disease · doi:10.1007/s11011-022-01095-1 · Cited by 91
“The medications used widely are selective serotonin reuptake inhibitors (SSRIs), Tricyclic antidepressants (TCAs), Serotonin norepinephrine reuptake inhibitors (SNRIs), Norepinephrine reuptake inhibitors (NRIs), Norepinephrine dopamine reuptake inhibitors (NDRIs) and atypical antidepressants (Kupfer 2005).”
BackgroundKim, N., Huh, H.-J., & Chae, J. (2015) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2015.04.009 · Cited by 90
“respond to first-line antidepressant treatment and at least 60-70% of patients fail to achieve a complete remission, with a high relapse rate [5].”
BackgroundMadhoo, M., Keefe, R. S., Roth, R. M., Sambunaris, A., Wu, J., Trivedi, M. H., Anderson, C. S., & Lasser, R. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2013.334 · Cited by 74
“Major depressive disorder (MDD) is often chronic and/or recurrent (Kupfer, 2005); the estimated lifetime prevalence is 16% (Kessler et al, 2003).”
BackgroundAugmentation treatment in major depressive disorder: focus on aripiprazole
Berman, R. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s3369 · Cited by 74
“Early achievement of symptomatic remission is critical to the long-term success of treatment (Kupfer 2005).”
Agrawal, K., Chakraborty, P., Dewanjee, S., Arfin, S., Das, S. S., Dey, A., Moustafa, M., Mishra, P. C., Jafari, S. M., Jha, N. K., et al. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104955 · Cited by 65
Duval, F., Lebowitz, B. D., & Macher, J. P. (2006) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2006.8.2/fduval · Cited by 75
“Schematically, one may categorize the treatment of depression into three phases: acute, continuation, and maintenance.(3,4) As summarized in Table I, each phase is defined by specific aims and strategies.”
BackgroundMahlich, J., Tsukazawa, S., & Wiegand, F. (2018) · Drugs - Real World Outcomes · doi:10.1007/s40801-017-0126-5 · Cited by 49
“2% [18], and the 12-month prevalence is 6.”
BackgroundDell’Osso, B., Albert, U., Carrà, G., Pompili, M., Nanni, M. G., Pasquini, M., Poloni, N., Raballo, A., Sambataro, F., Serafini, G., et al. (2020) · Annals of General Psychiatry · doi:10.1186/s12991-020-00306-2 · Cited by 52
Montgomery, S. (2006) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(06)70009-8 · Cited by 51
“However, the SSRIs and SNRIs are associated with side effects of their own, such as gastrointestinal problems, weight gain, sexual dysfunction, drowsiness and sedation, and discontinuation symptoms, all of which contribute to a reduction in compliance and may lead to premature cessation of treatment (Kupfer, 2005; Mon…”
BackgroundScheinfeld, N. S., Sundaram, M., Teixeira, H. D., Gu, Y., & Okun, M. M. (2016) · Dermatology Online Journal · doi:10.5070/d3223030360 · Cited by 45
“Furthermore, the limited duration of the double-blind period may not have allowed full resolution of depressive symptoms, which typically require years of maintenance treatment [32].”
BackgroundBiomaterials for Drugs Nose–Brain Transport: A New Therapeutic Approach for Neurological Diseases
Cassano, R., Servidio, C., & Trombino, S. (2021) · Materials · doi:10.3390/ma14071802 · Cited by 40
“At present, the main pharmacological treatments act primarily on the monoaminergic system by increasing the synaptic levels of monoamines such as serotonin, norepinephrine, and dopamine and include selective serotonin reuptake inhibitors, that act mainly on the serotonin transporter (SERT) such as fluoxetine, paroxeti…”
BackgroundMangoo, S., Erridge, S., Holvey, C., Coomber, R., Barros, D. A. R., Bhoskar, U., Mwimba, G., Praveen, K., Symeon, C., Sachdeva-Mohan, S., et al. (2022) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2022.2161894 · Cited by 38
“Antidepressant medications are a key component of depression treatment [2].”
BackgroundBosch, P., van den Noort, M., Staudte, H., & Lim, S. (2015) · EXPLORE · doi:10.1016/j.explore.2015.04.004 · Cited by 38
The neurodegenerative hypothesis of depression and the influence of antidepressant medications
Hall, S., Parr, B.-A., Hussey, S., Anoopkumar‐Dukie, S., Arora, D. S., & Grant, G. D. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176967 · Cited by 27
Epidemiology of treatment resistant depression among major depressive disorder patients in Israel
Sharman Moser, S., Chodick, G., Gelerstein, S., Barit Ben David, N., Shalev, V., & Stein-Reisner, O. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-04184-8 · Cited by 23
“Whereas there are no clinical trials that recommend combination therapy and the increased effectiveness is debated [57– 60], there is some evidence to suggest that combination therapy may be effective particularly in the elderly [61], and the combination of venlafaxine and mirtazapine may be particularly effective in…”
BackgroundEMSAM (deprenyl patch): how a promising antidepressant was underutilized
Asnis, G. M., & Henderson, M. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s59107 · Cited by 23
“For example, psychotic depression responds poorly to antidepressants alone compared to antidepressants plus antipsychotics or electroconvulsive therapy.(58) As described N eu ro ps yc hi at ric D is ea se a nd T re at m en t d ow nl oa de d fr om h ttp s: //w w w .”
Antos, Z., Żukow, X., Bursztynowicz, L., & Jakubów, P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413658 · Cited by 21
“…as tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs), selective serotonin reup-take inhibitors (SSRIs), and norepinephrine reuptake inhibitors (SNRIs), act by regulating monoamines in the central nervous system, increasing serotonergic and noradrenergic neurotransmission [16].”
Lewis, V., Rodrigue, B., Arsenault, E., Zhang, M., Taghavi‐Abkuh, F., Silva, W. C. C., Myers, M., Matta‐Camacho, E., & Aguilar‐Valles, A. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15652 · Cited by 21
“There are several pharmacological options available to treat MDD, of which the frontline treatments include monoamine reuptake inhibitors (e.g., selective serotonin reuptake inhibitors [SSRIs] & selective norepinephrine reuptake inhibitors [SNRIs]) and tricyclic antidepressants (Kupfer, 2005).”
BackgroundLekman, M., Paddock, S., & McMahon, F. J. (2008) · Molecular Diagnosis & Therapy · doi:10.1007/bf03256297 · Cited by 22
“[15-17] The lifetime prevalence, according to these (talk therapies, behavior therapies) and pharmacologic agents are reports, is estimated to be 16–20%, the highest prevalence among now available to treat depression.[7,8] However, today’s treatments the psychiatric diseases.”
BackgroundHerbal Approaches in the Management of Mental Depression
Garg, V., Garg, P., & Alambayan, J. (2022) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527321666220128091408 · Cited by 19
Nutraceuticals in mood disorders: current knowledge and future directions
Travica, N., Teasdale, S. B., & Marx, W. (2022) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000826 · Cited by 16
“Consequently, many people living with mood disorders do not achieve the full remission of symptoms [10].”
BackgroundKim, H. (2024) · Behavioral Sciences · doi:10.3390/bs14030241 · Cited by 15
“Preventive intervention is paramount because substance use not only increases individual, economic, and social costs [23] but also tends to accompany other substance use, which can lead to more serious problems [32].”
BackgroundDong, D., Lei, T., Song, M., Ma, L., & Zhao, H. (2020) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2020.02.014 · Cited by 13
RetractedHierarchical Structure of Depression Knowledge Network and Co-word Analysis of Focus Areas
Yu, Q., Wang, Z., Li, Z., Liu, X., Agyeman, F. O., & Wang, X. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.920920 · Cited by 13
“Extant studies have demonstrated the relevance of identifying and focusing on the rapid treatment of depression to avoid depression severity and suicidal acts (Ormel et al., 2019; Kupfer, 2022).”
BackgroundInfluentialFarooq, S., Singh, S. P., Burke, D. L., Naeem, F., & Ayub, M. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.03.024 · Cited by 13
Cell Type‐Specific mTORC1 Signaling and Translational Control in Synaptic Plasticity and Memory
Huang, Z., Mahmood, N., Wiebe, S. A., Khoutorsky, A., Lacaille, J., & Sonenberg, N. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70281 · Cited by 12
Apolinário-Hagen, J., Drüge, M., Hennemann, S., & Breil, B. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-33-6044-0_17 · Cited by 10
Piotrowski, P., Gondek, T. M., Rymaszewska, J., Beszłej, J. A., Czachowski, S., Parmentier, H., & Kurpas, D. (2017) · Family Medicine & Primary Care Review · doi:10.5114/fmpcr.2017.69300 · Cited by 9
Early augmentation by using neuromodulation in psychiatric disorder: a kaleidoscopic view
Kar, S. K., & Menon, V. (2021) · CNS Spectrums · doi:10.1017/s1092852921000237 · Cited by 9
“Evidence supports that early achievement of remission is key to treatment success.(4,5) In a study, patients with major depressive disorder with inadequate response to antidepressants received early augmentation with antipsychotic medications.”
BackgroundDepression in vascular pathologies: the neurologist's point of view
Moretti, R., Bernobich, E., Francesca, E., Torre, P., Rodolfo, A., Angelis, L. D., & Bellini, G. (2011) · Vascular Health and Risk Management · doi:10.2147/vhrm.s20147 · Cited by 11
“In addition, research into the possible role of oxidative stress in TCA-induced cardiotoxicity has found that free radical generation and oxidative stress play a role in clomipramine-induced cardiotoxicity.(60) TCAs may induce sinus tachycardia in many patients and orthostatic hypotension occurs in up to 20% of patien…”
Recent approaches to the diagnosis and therapy of monopolar depression
Petelin, D. S., & Volel, B. A. (2023) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202312310133 · Cited by 7
Depression, an unmet health need in Africa: Understanding the promise of ketamine
Millen, A. M. E., Daniels, W. M. U., & Baijnath, S. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28610 · Cited by 8
“…treatment and management of depression including monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), noradrenaline reuptake inhibitors (NRIs) and mood stabilizers [34,35].”
BackgroundProbiotics in Depression Management: Efficacy, Mechanisms and Future Directions
Lee, L. (2025) · Progress In Microbes & Molecular Biology · doi:10.36877/pmmb.a0000459 · Cited by 10
Manji, I., Cepalo, T., Ledesma, S., & Fallavollita, P. (2023) · Creativity Research Journal · doi:10.1080/10400419.2023.2168895 · Cited by 6
“Unfortunately, by attempting to eliminate the impact of various dementia-related symptom(s), through medications, there is an offset-ting chance that other side effects can harm the PwD (Kongpakwattana et al., 2018; Kupfer, 2005).”
Global Health Challenges: Nutrition and Management
Srivastava, S., Bisht, A. T., Laxmaiah, A., & Seetha, A. (2024) · CRC Press eBooks · doi:10.1201/9781003354024 · Cited by 7
Ruívo, M., Frontini, R., & Pernencar, C. A. D. C. (2023) · Procedia Computer Science · doi:10.1016/j.procs.2023.01.400 · Cited by 5
O’Connor, H., Vater, C. H., DiSalvo, M., Faraone, S. V., & Wozniak, J. R. (2023) · Journal of Attention Disorders · doi:10.1177/10870547231218045 · Cited by 6
“…overall side effects (Biederman & Spencer, 2008), few articles address their safety and efficacy in children with ADHD and comorbid BPD. Pediatric MDD and BPD are best treated with antidepressants and mood stabilizers, respectively (Kupfer, 2005), and may worsen when treated with stimulants.”
BackgroundEffects of Anesthetics on the Central Nervous System
Liu, Z., & Song, S. (2025) · Springer eBooks · doi:10.1007/978-3-031-85156-8_7 · Cited by 5
Lin, Y., Tao, H., Wang, L., Sun, G., Zhao, S., & An, B. (2026) · Scientific Reports · doi:10.1038/s41598-026-45237-2 · Cited by 3
Chen, B. K., Whye, A., Matthews, L. C., Moniz, T., Mendez‐David, I., Gardier, A. M., David, D. J. P., Johns, S., Weisblum, E., & Denny, C. A. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02107-1 · Cited by 3
Clinical Implication of Meditation in Psychiatry : Focused on Mindfulness Meditation
Huh, H. J., Han, S., Park, Y. N., & Chae, J. (2015) · 신경정신의학 · doi:10.4306/jknpa.2015.54.4.406 · Cited by 3
Pharmacotherapy of Functional Disorders in Children
Probst, L. A., & Burgess, J. L. (2014) · Springer eBooks · doi:10.1007/978-1-4899-8074-8_26 · Cited by 3
The Global Landscape of Neuropsychiatric Prescribing Practices of Nurses: A Scoping Review
Naidoo, M., Filmalter, C. J., & Cordier, W. (2025) · International Journal of Mental Health Nursing · doi:10.1111/inm.70101 · Cited by 2
“Neuropsychiatric pharmacotherapy is determined based on the level of symptom severity, current functional impairment of the patient, the duration of the depression, the presence of psychotic symptoms, level of suicidality, and previous illness and treatment history (Kupfer 2005).”
Nayak, J., Prasanna, S., & Das, P. (2021) · International Journal of Current Research and Review · doi:10.31782/ijcrr.2021.131524 · Cited by 1
Für jeden Patienten den optimalen Wirkstoff finden: Antidepressive Pharmakotherapie
Lieb, M., Rupprecht, R., & Baghai, T. C. (2012) · NeuroTransmitter · doi:10.1007/s15016-012-0565-x · Cited by 2
Biomarker in der Depressionsbehandlung: mehr als nur Worte?
Bosch, O. G., & Breitenstein, B. (2015) · Zeitschrift für Psychiatrie Psychologie und Psychotherapie · doi:10.1024/1661-4747/a000244 · Cited by 3
Geschlechtsunterschiede bei der Akupunkturbehandlung von Patienten mit Depressionen
Bosch, P., Lim, S., Staudte, H., Lee, S., Yeo, S., Litscher, D., Litscher, G., Wang, L., & van den Noort, M. (2019) · Deutsche Zeitschrift für Akupunktur · doi:10.1007/s42212-019-0189-1 · Cited by 1
Carvalho, S., Caetano, F., Pinto‐Gouveia, J., Mota-Pereira, J., Maia, D., Pimentel, P., Priscila, C., & Gilbert, P. (2020) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2020.1790657 · Cited by 1
Linking depression, mRNA translation, and serotonin
Arsenault, E., Ahmed, A. A., Daneshmend, A., Jihad-Mohamad, Z., Matta‐Camacho, E., Nyveld, M., Taghavi‐Abkuh, F., Zhang, M., Sonenberg, N., Lacaille, J., et al. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-817935-2.00009-x · Cited by 1
محمد, ب. ا. ف. ا., & محمد, س. ا. ف. ا. (2022) · Journal of Pure & Applied Sciences · doi:10.51984/jopas.v21i4.2132 · Cited by 1
“After chronic administration of this drug some patients complained of major depression in 1950's ([7]).”
BackgroundIntroduction to Complex Brain Disorders, Currently Available Therapies, and Their Limitations
Kendre, S., Kumbhare, M., & Mishra, A. (2024) · Springer eBooks · doi:10.1007/978-981-97-2859-6_1 · Cited by 1
Antidepressant-Antianxiety Agents
Baldessarini, R. J. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3710-9_4 · Cited by 1
DFP: Antidepressive Pharmakotherapie: Aktueller Stand und neue Entwicklungen
Baghai, T., Hp, V., & Hj, M. (2011) · Journal für Kardiologie (Krause & Pachernegg GmbH)
Needles on the couch: acupuncture in the treatment of depression, schizophrenia and sleep disorders
Bosch, M. P. C. (2015) · Radboud Repository (Radboud University) · Cited by 21
Zirngibl, C. (2014) · Journal of Depression & Anxiety · doi:10.4172/2167-1044.1000154
“Treatment Goals Traditionally the treatment of depressive disorders can be subdivided in acute, maintenance, and in prophylactic treatment [25,26].”
BackgroundA Review and Conjectures of Therapies for Depression
Aiyang, J. (2021) · Advances in Social Science, Education and Humanities Research/Advances in social science, education and humanities research · doi:10.2991/assehr.k.210617.093
Salama, A., Elhadidy, M. E., EL-Kassaby, M. I., & Farrag, A. R. H. (2022) · Egyptian Pharmaceutical Journal · doi:10.4103/epj.epj_53_21
Chafee, H. (2022) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.19579795
SÍNDROME DE BURNOUT EM PROFISSIONAIS DA SAÚDE: REVISÃO NARRATIVA
Nascimento, F., Ximenes, L. A., do Nascimento, L. A., Bastos, M. C., Rocha, N. R. A., Nascimento, S., Mello, D. B., & Macedo, A. B. T. (2023) · Editora Científica Digital eBooks · doi:10.37885/230713850
Manji, I. (2021) · uO Research (University of Ottawa) · doi:10.20381/ruor-27191
Michaud, D. (2023) · Corpus Université Laval (Université Laval)
Wang, T., Guo, Y., 李小迎, Wang, X., Zhang, L., & Liu, J. (2026) · Behavioural Brain Research · doi:10.1016/j.bbr.2026.116231
Hazeltine, D. (2026) · CUNY Academic Works (City University of New York)
Metadata
- Authors
- Kupfer, D. J.
- Affiliations
- University of Pittsburgh (US)
- Corresponding author
- Kupfer, David J.
- ORCID
- Kupfer, David J.
- Venue
- Dialogues in Clinical Neuroscience
- Publisher
- Informa UK Limited
- Published
- 2005-09-30
- Volume
- 7
- Issue
- 3
- Pages
- 191-205
- ISSN
- 1294-8322 (ISSN-L)
- 1958-5969
- PMC
- PMC3181740
- OpenAlex
- W16698172
- Cited by
- 69
- References
- 124
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 5 · 2023: 5 · 2022: 11 · 2021: 6 · 2020: 4 · 2019: 2 · 2018: 1 · 2017: 4 · 2016: 1 · 2015: 5 · 2014: 3 · 2013: 1 · 2012: 4
- FWCI
- 1.49
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- Locations
- Dialogues in Clinical Neuroscience (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (MH30915)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- depression, pharmacotherapy, antidepressants, depression severity assessment, suicidality, acute phase treatment, continuation treatment, maintenance therapy, recurrence risk, comorbidities, psychotic depression, bipolar depression, young patients, biomarkers, therapeutic target
- MeSH terms
- Adolescent, Antidepressive Agents, Brain, Child, Depression, Female, Humans, Male
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.